PMN (ProMIS Neurosciences) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ProMIS Neurosciences's cash to debt ratio for the quarter that ended in Sep. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ProMIS Neurosciences could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for ProMIS Neurosciences's Cash-to-Debt or its related term are showing as below:

PMN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, ProMIS Neurosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was No Debt.

PMN's Cash-to-Debt is ranked better than
99.87% of 1487 companies
in the Biotechnology industry
Industry Median: 7.48 vs PMN: No Debt

ProMIS Neurosciences Cash-to-Debt Historical Data

The historical data trend for ProMIS Neurosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ProMIS Neurosciences Cash-to-Debt Chart

ProMIS Neurosciences Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

4.35

No Debt

ProMIS Neurosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of ProMIS Neurosciences's Cash-to-Debt

For the Biotechnology subindustry, ProMIS Neurosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProMIS Neurosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

ProMIS Neurosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ProMIS Neurosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

ProMIS Neurosciences had no debt ⁽¹⁾.

ProMIS Neurosciences's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

ProMIS Neurosciences had no debt ⁽¹⁾.

ProMIS Neurosciences (NAS:PMN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

ProMIS Neurosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

23J0:Germany 23J0:Germany

Address

1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2

Website

https://www.promisneurosciences.com

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Executives

Neil Cashman	director, officer: Chief Scientific Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Madge K. Shafmaster	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel	officer: Chief Medical Officer	C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar	10 percent owner	33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel	director, officer: Chief Executive Officer	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury	officer: Principal Accounting Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant	officer: Chief Operating Officer	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan	officer: Chief Development Officer	PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams	director, officer: Chairman and CEO	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory	director	830 WINTER STREET, WALTHAM MA 02451
Neil K Warma	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman	director	4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm	director	C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2